2011-02-07 18:32:23 UTC

Rifaximin Improves Driving in Hepatic Encephalopathy

Feb. 7, 2011

Doctors found that in patients with cirrhosis and minimal hepatic encephalopathy, driving performance significantly improved after treatment with rifaximin.

Patients with cirrhosis and minimal hepatic encephalopathy have driving difficulties, but the effects of therapy on driving performance are unclear. In a study appearing in Gastroenterology, doctors concluded that patients with minimal hepatic encephalopathy significantly improve driving simulator performance after treatment with rifaximin, compared with placebo.

Gastroenterology; 2011: 140(2): 478-87

More on Cirrhosis

Blog: Special 15th Anniversary Collection from Clinical Gastroenterology and Hepatology

Oct. 11, 2017

Celebrate this milestone with a look back at landmark articles, commentaries and reviews. Read more on the AGA Journals blog.

Spotlight on Fellow-Led Quality Improvement Projects

Oct. 3, 2017

These 19 projects presented at DDW® 2017 showcase the extensive work being done by fellows to improve the quality of care provided to GI patients.

Risk of Hepatocellular Cancer in HCV Patients Treated With Direct-Acting Antiviral Agents

Oct. 1, 2017

Among HCV-infected patients treated with DAAs, SVR is associated with a considerable reduction in the risk of HCC; however, the risk for HCC remained high in patients with cirrhosis at the time of SVR.